Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Lung Cancer Video Library - Can Serum Tumor Markers Be Used in the Management of Lung Cancer?
gracevideo
Image
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC describes the use of serum tumor markers in various types of cancer, and the lack of a useful serum tumor marker in lung cancer.
Transcript
Now, we’ve talked about ways of doing what we call liquid biopsies, and trying to measure tumors in the blood, but we don’t have any system with those technologies, as of yet — this will be summer of 2015, that we can actually use them to track or measure cancer and its response to therapy.
There are some other cancers out there, such as those that involve the bowel, or the colon, or the esophagus, in which, after you’ve already diagnosed a cancer, you can use a blood marker. One is called CEA, or carcinoembryonic antigen. This CEA is something that will rise when there is more cancer, or fall when there is less cancer. So, if one is being treated with chemotherapy, a physician can follow this level during the course of therapy, and after therapy, they can follow the levels and see if they begin to rise.
CA 125 in ovarian cancer is another example of where you have a blood marker that will actually rise or fall in the response for therapy. You can also use CA 125 to detect if there is cancer, and you can also use something we call PSA, or prostate specific antigen, to diagnose and follow prostate cancer. It’s an important distinction on these blood markers — some we can use to actually help diagnose: PSA, CA 125, and some we can’t use to diagnose as accurately, but we can use them to see the effect of treatment, after you’ve been diagnosed and started on therapy, something like CEA.
Unfortunately, in lung cancer, we don’t have anything right now that helps us follow the course and response of a lung cancer during treatment. Really, we rely on two things. One is serial radiographic assessment, with CAT scans, PET scans, wherever the site of disease is, and two, how the patient, themselves, is feeling. So, that’s a clinical response that we look for — we also, then, look for a radiographic response, and if both the patient is feeling better, and the tumor is shrinking, that is the best case scenario.
But right now, there isn’t anything we have, as far as a blood marker, that we use to follow serially.
Video Language
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial. We want to hear from you!
Image
Video
The Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón presentado el 9 de agosto de 2025 has now ended.
¡Los vídeos están disponibles BAJO DEMANDA!
Las versiones completas sin editar del Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón de agosto de 2025 ya están disponibles BAJO DEMANDA. Estos temas se editarán y se ofrecerán en forma de vídeos más cortos en las próximas semanas.
Image
Article
Da click aquí para más información y para registrarte ahora
Online Community
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.